Clinical trial / 2012
Omega-3 fatty acids did not prevent cognitive decline in coronary heart disease patients.
In a randomized, double-blind, placebo-controlled trial, 2,911 coronary patients aged 60 to 80 years received margarines delivering 400 mg/day EPA-DHA, 2 g/day ALA, both, or placebo for 40 months. Changes in Mini-Mental State Examination scores did not differ between EPA-DHA and placebo (-0.65 vs -0.69 points, P = .44) or ALA and placebo (-0.60 vs -0.74 points, P = .12). Risk of cognitive decline was 1.03 (95% CI: 0.84-1.26) for EPA-DHA and 0.90 (95% CI: 0.74-1.10) for ALA.
- Study type
- Randomized controlled trial
- Who was studied
- 2,911 coronary heart disease patients aged 60 to 80 years
- What was measured
- Global cognitive decline and Mini-Mental State Examination score
THE PAPER
Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients.
Geleijnse JM, Giltay EJ, Kromhout D. Alzheimers Dement, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.